Phoremost reports Series B extension
British protein degrader specialist PhoreMost Ltd has extended its €33m Series B financing to $50M and plans to advance its oncology and inflammation degrader programmes.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Funding for green insecticides
/in News/by Thomas GabrielczykAgri-biotech SOLASTA Bio Ltd. has raised US$14m in a Series A funding round led by Forbion. With the money, the UK company will advance its first-of-a kind peptide-based bioinsecticide.
AZ’s lung cancer drug disappoints
/in News/by Thomas GabrielczykA Phase III trial evaluating AstraZeneca and Daiichi Sankyo’s potential “blockbuster” lung cancer drug Dato-DXd showed no significant improvement over standard chemotherapy. Investors reacted quickly: AstraZeneca’s share price dropped 5% following the announcement.
Epsilogen Ltd completes £12.5m Series B expansion
/in News/by Thomas GabrielczykA new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept for MOv18 IgE.
Swiss RNA maker Haya in huge licence deal
/in News/by Thomas GabrielczykSwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions.
Roche with good interim clinical results
/in News/by Thomas GabrielczykRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression after one year in patients with relapsing multiple sclerosis
Individor set to waive AEF0117 licence after Phase IIb failure
/in News/by Thomas GabrielczykFollowing the failure of Aelis Farma’s lead candidate AEF0117 in a Phase IIb study in patients with cannabis use disorder or cannabis-induced psychosis, Individor plc has stated that it will not exercise its licence option until Aelis has submitted a final data analysis.
Nxera Pharma Ltd collects clinical US$35m milestone
/in News/by Thomas GabrielczykNxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568.
Researchers present AI-guided protein design tool
/in News/by Thomas GabrielczykDanish AI expert Francesco Pesce and collegues have expanded the toolbox for computational protein design. Their new algorithm will facilitate the design of proteins whose functions exploit the many properties afforded by protein disorder.
Amferia partners with Biokema expanding into Switzerland
/in News/by Thomas GabrielczykSwedish antimicrobial specialist Amferia AB has inked a contract is with the Swiss animal health company Biokema SA for commercialisation of Amferia’s proprietary antimicrobial wound care technology in Switzerland.